Olix Pharmaceuticals, Inc. is based in South Korea. The head office is in Suwon. The enterprise currently operates in the Research and Development in Nanotechnology sector. It was first established on February 26, 2010. It currently has a total number of 76 (2025) employees. In its most recent financial highlights, the company reported a net sales revenue increase of 158.35% in 2025. Its total assets grew by 174.2% over the same period. The net profit margin of Olix Pharmaceuticals, Inc. increased by 608.84% in 2025.

Headquarters
1014, 17, Daehak4-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do
Suwon; Gyeonggi;

Contact Details: Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Website: http://www.olixpharma.com

Basic Information

Total Employees:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Outstanding Shares:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Registered Capital:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Financial Auditors:

Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Incorporation Date:

February 26, 2010

Key Executives

Purchase this report to view the information.

Chief Executive Officer

Ownership Details

Purchase this report to view the information.

26.4%

Purchase this report to view the information.

5.8%

Purchase this report to view the information.

3.1%

Subsidiaries

Olix Us Inc

올릭스 주식회사

Company Performance

Financial values in the chart are available after Olix Pharmaceuticals, Inc. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.

Net sales revenue

158.35%▲

Total Operating Revenue

184.53%▲

Operating Profit

23.37%▲

EBITDA

4.71%▲

Net Profit/Loss for the Period

61.28%▲

Total Assets

174.2%▲

Total Equity

712.44%▲

Operating Profit Margin

484.65%▲

Net Profit Margin

608.84%▲

Return on Equity (ROE)

209.61%▲

Debt / Equity

-196.64%▼

Quick Ratio

6.09%▲

Cash Ratio

0.17%▲

Olix Pharmaceuticals, Inc. (South Korea)

Similar companies